Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hypersensitivity pneumonitis: new concepts and classifications

Abstract

The clinical and pathologic diagnosis of hypersensitivity pneumonitis has been confounded by conflicting definitions, with two recent guidelines suggesting that hypersensitivity pneumonitis simply be diagnosed as nonfibrotic or fibrotic. Nonfibrotic hypersensitivity pneumonitis is usually characterized by a bronchiolocentric chronic interstitial inflammatory infiltrate, frequently but by no means always with associated granulomas or giant cells. Fibrotic hypersensitivity pneumonitis may take the form of interstitial fibrosis confined to the peribronchiolar regions, or fibrotic nonspecific interstitial pneumonia, or a process similar to and sometimes indistinguishable from usual interstitial pneumonia/idiopathic interstitial fibrosis, but the exact pathologic features that favor a diagnosis of fibrotic hypersensitivity pneumonitis are disputed. Granulomas/giant cells are much less frequent in fibrotic compared to nonfibrotic hypersensitivity pneumonitis. Extensive peribronchiolar metaplasia, particularly peribronchiolar metaplasia affecting more than half the bronchioles, supports a diagnosis of fibrotic hypersensitivity pneumonitis over usual interstitial pneumonia, as does the presence of predominantly peribronchiolar disease with relative subpleural sparing. Clinical and CT features are crucial to the diagnosis of hypersensitivity pneumonitis: sparing of the lung bases, centrilobular nodules, air-trapping, or the triple density sign with fibrosis favor a diagnosis of fibrotic hypersensitivity pneumonitis. At this point there are no molecular tests that reliably separate fibrotic hypersensitivity pneumonitis from other forms of interstitial lung disease. Currently the separation of fibrotic hypersensitivity pneumonitis from usual interstitial pneumonia is crucial to treatment (immunosuppressives for the former, anti-fibrotics for the latter) but this approach is changing and all progressive fibrosing interstitial pneumonias will probably be treated with antifibrotics in the future.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Nonfibrotic hypersensitivity pneumonitis (HP).
Fig. 2: Nonfibrotic hypersensitivity pneumonitis (HP).
Fig. 3: Fibrotic hypersensitivity pneumonitis (HP).
Fig. 4: Fibrotic hypersensitivity pneumonitis (HP).
Fig. 5: Fibrotic hypersensitivity pneumonitis (HP).
Fig. 6: Single nucleotide polymorphisms associated with various forms of fibrosing interstitial pneumonias.

Data availability statement

There are no data beyond the original published articles cited in the paper.

References

  1. 1.

    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

    PubMed  Article  Google Scholar 

  3. 3.

    Walsh SL, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;4:557–65.

    PubMed  Article  Google Scholar 

  4. 4.

    Morell F, Villar A, Montero MÁ, Muñoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med. 2013;1:685–94.

    PubMed  Article  Google Scholar 

  5. 5.

    Churg A, Bilawich A, Wright JL. Pathology of chronic hypersensitivity pneumonitis what is it? What are the diagnostic criteria? Why do we care? Arch Pathol Lab Med. 2018;142:109–19.

    PubMed  Article  Google Scholar 

  6. 6.

    Churg A. Centrilobular fibrosis in fibrotic (chronic) hypersensitivity pneumonitis, usual interstitial pneumonia, and connective tissue disease-associated interstitial lung disease. Arch Pathol Lab Med. 2020;144:1509–1516.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Hashisako M, Tanaka T, Terasaki Y, Uekusa T, Achcar RD, Aswad BI, et al. Interobserver agreement of usual interstitial pneumonia diagnosis correlated with patient outcome. Arch Pathol Lab Med. 2016;140:1375–1382.

    PubMed  Article  Google Scholar 

  8. 8.

    Tanizawa K, Ley B, Vittinghoff E, Elicker BM, Henry TS, Wolters PJ, et al. Significance of bronchiolocentric fibrosis in patients with histopathological usual interstitial pneumonia. Histopathology .2019;74:1088–97.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M. Diagnosis of hypersensitivity pneumonitis in adults. an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e36–69.

    PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Fernández Pérez ER, Travis WD, Lynch DA, Brown KK, Johannson KA, Selman M, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST Guideline and expert panel report. Chest, Apr 13:S0012-369200686-3. https://doi.org/10.1016/j.chest.2021.03.066. Online ahead of print. PMID: 33861992.

  11. 11.

    Morell F, Villar A, Ojanguren I, Muñoz X, Cruz MJ. Hypersensitivity pneumonitis: challenges in diagnosis and management, avoiding surgical lung biopsy. Semin Respir Crit Care Med. 2017;37:395–405.

    Google Scholar 

  12. 12.

    Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med. 2017;195:801–13.

    PubMed  Article  Google Scholar 

  13. 13.

    Ryerson CJ. Making sense of bronchoalveolar lavage lymphocytosis in fibrotic interstitial lung disease. Ann Am Thor Soc. 2020;17:1382–3.

    Article  Google Scholar 

  14. 14.

    Morell F, Roger À, Reyes L, Cruz MJ, Murio C, Muñoz X. Bird fancier’s lung: a series of 86 patients. Med (Baltim). 2008;87:110–30.

    Article  Google Scholar 

  15. 15.

    Muñoz X, Sánchez-Ortiz M, Torres F, Villar A, Morell F, Cruz MJ. Diagnostic yield of specific inhalation challenge in hypersensitivity pneumonitis. Eur Respir J. 2014;44:1658–1565.

    PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Silva CI, Müller NL, Lynch DA, Curran-Everett D, Brown KK, Lee KS, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology .2008;246:288–297.

    PubMed  Article  Google Scholar 

  17. 17.

    Hypersensitivity pneumonitis. In, Churg A, Muller NL: Atlas of interstitial lung disease pathology, 2nd ed. New York: Wolters Kluwer; 2020. p. 115–35.

  18. 18.

    Churg A, Wright JL, Ryerson CJ. Pathologic separation of chronic hypersensitivity pneumonitis from fibrotic connective tissue disease-associated interstitial lung disease. Am J Surg Pathol. 2017;41:1403–9.

    PubMed  Article  Google Scholar 

  19. 19.

    Castonguay MC, Ryu JH, Yi ES, Tazelaar HD. Granulomas and giant cells in hypersensitivity pneumonitis. Hum Pathol. 2015;46:607–13.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Wright JL, Churg A, Hague CJ, Wong A, Ryerson CJ. Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. Mod Pathol. 2020;33:616–25.

    PubMed  Article  PubMed Central  Google Scholar 

  21. 21.

    Takemura T, Akashi T, Kamiya H, Ikushima S, Ando T, Oritsu M, et al. Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology .2012;61:1026–35.

    PubMed  Article  Google Scholar 

  22. 22.

    Cavazza A, Colby TV, Dubini A, Tomassetti S, Ravaglia C, Poletti V, et al. Transbronchial cryobiopsy in the diagnosis of diffuse lung disease. Surg Pathol Clin. 2020;13:197–208.

    PubMed  Article  Google Scholar 

  23. 23.

    Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA, et al. Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease alliance (COLDICE) Investigators. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet. Respir Med. 2020;8:171–81.

    CAS  Google Scholar 

  24. 24.

    Romagnoli M, Colby TV, Berthet JP, Gamez AS, Mallet JP, Serre I, et al. Poor concordance between sequential transbronchial lung cryobiopsy and surgical lung biopsy in the diagnosis of diffuse interstitial lung diseases. Am J Respir Crit Care Med. 2019;199:1249–56.

    PubMed  Article  Google Scholar 

  25. 25.

    Cooper WA, Mahar A, Myers JL, Grainge C, Corte TJ, Williamson JP, et al. Cryobiopsy for identification of usual interstitial pneumonia and other interstitial lung disease features: further lessons from COLDICE, a prospective multi-center study. Am J Respir Crit Care Med. 2020 Dec 7. https://doi.org/10.1164/rccm.202009-3688OC. Epub ahead of print. PMID: 33285079.

  26. 26.

    Churg A, Wright JL. Morphologic features of fibrotic hypersensitivity pneumonitis in transbronchial cryobiopsies versus video-assisted thoracoscopic biopsies: an in silico study. Arch Pathol Lab Med. 2021;145:448–52.

    PubMed  Article  Google Scholar 

  27. 27.

    Smith ML, Hariri LP, Mino-Kenudson M, Dacic S, Attanoos R, Borczuk A, et al. Histopathologic assessment of suspected idiopathic pulmonary fibrosis: where we are and where we need to go. Arch Pathol Lab Med. 2020;144:1477–89.

    PubMed  Article  Google Scholar 

  28. 28.

    Hariri LP, Smith ML, Mino-Kenudson M, Allen TC, Attanoos R, Borczuk A, et al. Pulmonary pathology society perspective on the 2018 American thoracic society, european respiratory society, japanese respiratory society, and latin american thoracic society idiopathic pulmonary fibrosis clinical practice guidelines. Ann Am Thorac Soc. 2020;17:550–4.

    PubMed  Article  Google Scholar 

  29. 29.

    Sarcoid. In, Churg A, Muller NL: Atlas of Interstitial Lung Disease Pathology, 2nd ed. New York: Wolters Kluwer; 2020. p. 136–51.

  30. 30.

    Bronchiolitis. In, Churg A, Muller NL: Atlas of Interstitial Lung Disease Pathology, 2nd ed. New York: Wolters Kluwer; 2020. p. 223–37.

  31. 31.

    Graney BA, Fischer A. Interstitial pneumonia with autoimmune features. Ann Am Thorac Soc. 2019;16:525–33.

    PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Adegunsoye A, Vij R, Noth I. Integrating genomics into management of fibrotic interstitial lung disease. Chest .2019;155:1026–40.

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghof E, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5:639–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N. Engl J Med. 2017;379:2209–19.

    Article  Google Scholar 

  35. 35.

    MGJP Platenburg, Wiertz IA, van der Vis JJ, Crestani B, Borie R, Dieude P, et al. The MUC5B promoter risk allele for idiopathic pulmonary fibrosis predisposes to asbestosis. Eur Respir J. 2020;55:1902361.

    Article  Google Scholar 

  36. 36.

    Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, et al. Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study. Lancet Respir Med. 2021;9:285–94.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TV, Myers JL, et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 2019;7:487–96.

    PubMed  Article  Google Scholar 

  38. 38.

    Kheir F, Alkhatib A, Berry GJ, Daroca P, Diethelm L, Rampolla R. Using bronchoscopic lung cryobiopsy and a genomic classifier in the multidisciplinary diagnosis of diffuse interstitial lung diseases. Chest .2020;158:2015–25.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Richeldi L, Scholand MB, Lynch DA, Colby TV, Myers JL, Groshong SD, et al. Utility of a molecular classifier as a complement to high- resolution computed tomography to identify usual interstitial pneumonia. Am J Respir Crit Care Med. 2021;203:211–20.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Furusawa H, Cardwell JH, Okamoto T, Walts AD, Konigsberg IR, Kurche JS, et al. Chronic hypersensitivity pneumonitis, an interstitial lung disease with distinct molecular signatures. Am J Respir Crit Care Med. 2020;202:1430–44.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Fernández Pérez ER, Swigris JJ, Forssén AV, Tourin O, Solomon JJ, Huie TJ. et al. Identifying inciting antigen is associated improved survival patients chronic hypersensitivity pneumonitis. Chest. 2013;144:1644–51.

    PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest .2019;155:699–711.

    PubMed  Article  Google Scholar 

  43. 43.

    Churg A, Sin DD, Everett D, Brown K, Cool C. Pathologic patterns and survival in chronic hypersensitivity pneumonitis. Am J Surg Pathol. 2009;33:1765–70.

    PubMed  Article  Google Scholar 

  44. 44.

    Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, et al. Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest .2017;152:502–9.

    PubMed  Article  Google Scholar 

  45. 45.

    Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680–9.

    PubMed  Article  Google Scholar 

  46. 46.

    Sema M, Miyazaki Y, Tsutsui T, Tomita M, Eishi Y, Inase N. Environmental levels of avian antigen are relevant to the progression of chronic hypersensitivity pneumonitis during antigen avoidance. Immun Inflamm Dis. 2018;6:154–62.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest .2017;151:619–25.

    PubMed  Article  Google Scholar 

  48. 48.

    Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. INBUILD trial investigators. nintedanib in progressive fibrosing interstitial lung diseases. N. Engl J Med. 2019;381:1718–27.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147–57.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Study design, writing of manuscript: AC.

Corresponding author

Correspondence to Andrew Churg.

Ethics declarations

Funding statement

No specific funding was used for this paper.

Ethics approval and consent to participate

This project was approved by the University of British Columbia Research Ethics Board.

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Churg, A. Hypersensitivity pneumonitis: new concepts and classifications. Mod Pathol (2021). https://doi.org/10.1038/s41379-021-00866-y

Download citation

Search

Quick links